Xencor Inc(XNCR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 6:41 AM ET (Korea 10/28 19:41)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.17 | Insider Own | 5.87% | Shs Outstand | 74.3M | Perf Week | 20.25% |
| Market Cap | 2.23B | Forward P/E | - | EPS next Y | -11.2% | Insider Trans | -0.69% | Shs Float | 70.0M | Perf Month | 17.15% |
| Enterprise Value | 1.94B | PEG | - | EPS next Q | -0.33 | Inst Own | 109.34% | Short Float | 17.53% | Perf Quarter | 53.56% |
| Income | -0.16B | P/S | 21.24 | EPS this Y | -142.11% | Inst Trans | -0.52% | Short Ratio | 8.35 | Perf Half Y | 146.83% |
| Sales | 0.10B | P/B | 4.43 | EPS next 5Y | - | ROA | -20.36% | Short Interest | 12.27M | Perf YTD | 95.89% |
| Book/sh | 6.77 | P/C | 4.89 | EPS past 3/5Y | -10.21% -0.43% | ROE | -29.07% | 52W High | -10.74% ($33.60) | Perf Year | 110.16% |
| Cash/sh | 6.14 | P/FCF | - | Sales past 3/5Y | -8.62% 0.47% | ROIC | -25.44% | 52W Low | 189.06% ($10.38) | Perf 3Y | 79.04% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 10.25% | Gross Margin | 90.3% | Volatility(W/M) | 8.26% 6.4% | Perf 5Y | -23.02% |
| Dividend TTM | - | EV/Sales | 18.51 | Sales Y/Y TTM | -28.56% | Oper. Margin | -205.84% | ATR (14) | 1.9 | Perf 10Y | 45.87% |
| Dividend Ex-Date | - | Quick Ratio | 6.39 | EPS Q/Q | 30.99% | Profit Margin | -155.59% | RSI (14) | 71.02 | Recom | 1.36 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.39 | Sales Q/Q | 17.46% | SMA20 | 19.91% ($25.01) | Beta | 0.81 | Target Price | $40.25 |
| Payout | - | Debt/Eq | 0.34 | Earnings | 2026/8/5 | SMA50 | 17.34% ($25.56) | Rel Volume | 1.44 | Prev Close | $29.18 |
| Employees | 260 | LT Debt/Eq | 0.28 | EPS/Sales Surpr. | 63.82% 171.16% | SMA200 | 79.33% ($16.72) | Avg Volume(3M) | 1.47M | Price | $29.99 |
| IPO | 2013/12/3 | Option/Short | Yes/Yes | Trades | 20053 | Volume | 2,108,869 | Change | 2.78% |
🧬 Gencore (XNCR) is a US clinical-stage biotech company that designs antibody therapeutics based on its proprietary protein engineering platform, XmAb. It develops bispecific antibodies that recruit T cells to cancer cells, as well as antibodies for autoimmune diseases, and has established multiple licensing partnerships with global pharmaceutical companies to secure royalty and milestone revenue.
Over the past 1 year, on the higher side
11% below its 1-year high.
Traded more than usual. That is 144% of its average volume.
XNCR has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -142.1% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $2,124. Peers typically go for $1,261. It is about in line with its own 1-year average.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -23.0%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 109.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #91 of 594 in the industry
Based on market cap of $2B.
FAQ
What kind of company is XNCR?
XNCR belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of XNCR?
The market cap of XNCR is approximately $2.2B, ranking 1,970 within its sector.
What is the 52-week high and low for XNCR?
XNCR has recorded a 52-week high of $33.60 and a low of $10.38.
